How CA 125 is used in the routine follow-up of ovarian cancer: A survey of 29 Italian hospitals

被引:2
|
作者
Gion, M [1 ]
Barioli, P [1 ]
Ponti, A [1 ]
Torri, V [1 ]
Mione, R [1 ]
Dittadi, R [1 ]
机构
[1] Osped Civile Venezia, Ctr Reg Studio Indicatori Biochim Tumore, I-30122 Venice, Italy
关键词
tumor markers; CA; 125; ovarian cancer;
D O I
10.1159/000030017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor markers are currently monitored on a routine basis, However, their impact on the course of a disease is still under debate, This relative uncertainty leads to a subjective approach to their use, In order to evaluate the range in the pattern of tumor marker application we carried out a survey on the follow-up of patients with ovarian, breast, and colorectal carcinomas, This report concerns only ovarian cancer, Preliminary results showed that the number of markers used, the cutoff point and, probably of major importance, the management of patients with positive tumor marker vary considerably, When evaluating the institutional setting of the surveyed hospitals, a relatively poor interaction between clinicians and the laboratory staff was found, Actually, in about half of the investigated centers, clinical information is not provided to the laboratory staff and methodological aspects are not reported to clinicans, too, The first step to increase the effectiveness of tumor markers is to improve cooperation between persons assaying the markers and those using them, This is a mandatory task in order to both enable the application of recommendations provided by guidelines and to provide the means to verify their rate of acceptance.
引用
收藏
页码:269 / 274
页数:6
相关论文
共 50 条
  • [21] Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer
    Krell, Daniel
    Battistino, Fran Said
    Benafif, Sarah
    Ganegoda, Lochani
    Hall, Marcia
    Rustin, Gordon J. S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (06) : 1118 - 1122
  • [22] THE FOLLOW-UP OF OVARIAN-CANCER PATIENTS WITH BETA-2-MICROGLOBULIN AND CA-125
    HERNADI, Z
    MOLNAR, V
    JUHASZ, B
    POLKA, R
    MARGITAI, B
    ZENTRALBLATT FUR GYNAKOLOGIE, 1992, 114 (01): : 6 - 9
  • [23] CA 125 measurement during follow-up of breast cancer patients
    Bohmer, C
    Jager, W
    Lang, N
    GEBURTSHILFE UND FRAUENHEILKUNDE, 1996, 56 (11) : 625 - 628
  • [24] VALUE OF CA125 IN OVARIAN CANCER FOLLOW UP: AN ILLUSION OR REALITY?
    Fotopoulou, C.
    ANTICANCER RESEARCH, 2014, 34 (11) : 6811 - 6811
  • [25] The follow-up of ovarian cancer
    Vaidya, AP
    Curtin, JP
    SEMINARS IN ONCOLOGY, 2003, 30 (03) : 401 - 412
  • [26] LONG-TERM FOLLOW-UP OF OVARIAN-CANCER WITH MONTHLY DETERMINATIONS OF SERUM CA-125
    HOGBERG, T
    KAGEDAL, B
    GYNECOLOGIC ONCOLOGY, 1992, 46 (02) : 191 - 198
  • [27] Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125
    Abu Hassaan, Suher Othman
    DANISH MEDICAL JOURNAL, 2018, 65 (04):
  • [28] Is HE4 Superior over CA-125 in the Follow-up of Patients with Epithelial Ovarian Cancer?
    El Bairi, Khalid
    Afqir, Said
    Amrani, Mariam
    CURRENT DRUG TARGETS, 2020, 21 (10) : 1026 - 1033
  • [29] Routine follow-up after treatment for a gynecological cancer: a survey of practice
    Kew, FM
    Cruickshank, DJ
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (01) : 380 - 384
  • [30] Routine follow-up practices in patients with lymphoma: a nationwide survey by the Italian lymphoma foundation
    Broccoli, Alessandro
    Margiotta-Casaluci, Gloria
    Pagani, Chiara
    Steffanoni, Sara
    Viviani, Simonetta
    Zinzani, Pier Luigi
    Gini, Guido
    LEUKEMIA & LYMPHOMA, 2024, 65 (14) : 2207 - 2210